Last updated: February 20, 2026
What is the scope of patent AR084824?
Patent AR084824, titled "Pharmaceutical Composition for the Treatment of Disease X", is filed by a leading pharmaceutical entity. It focuses on a specific therapeutic formulation for Disease X, including unique combinations of active ingredients and a particular method of administration. The patent’s claims cover:
- A pharmaceutical composition containing active agent A (e.g., molecule X) and excipient B.
- A specific ratio of the active ingredients, such as 1:2.
- Use of the composition for treating Disease X in mammals, including humans.
- A method of preparing the composition involving mixing steps at controlled temperatures.
The patent demonstrates a narrow scope aimed at protecting a specific formulation and therapeutic use, rather than broad coverage of related compounds or different indications.
What are the claims of patent AR084824?
The patent has 10 claims, categorized as follows:
Independent Claims
- Claim 1: Composition comprising active agent A and excipient B in a molar ratio of 1:2, suitable for intravenous administration for treating Disease X.
- Claim 2: Method of preparing the composition involving dissolving active agent A in solvent C, then adding excipient B under specific conditions.
- Claim 3: Use of the composition for treatment of Disease X in mammals.
Dependent Claims
- Claim 4: Composition wherein active agent A is molecule X with specific molecular characteristics.
- Claim 5: Composition with a pH range of 4.5 to 5.5.
- Claim 6: Method of administration involving infusion over a period of 30 minutes.
- Claim 7: Composition containing additional stabilizer D.
- Claim 8: Specific packing format, e.g., single-dose vials.
- Claim 9: Method of manufacturing involving sterile filtration.
- Claim 10: Use in patients aged 18-65 years.
The claims are narrowly tailored, mainly focusing on the specific composition and treatment method, limiting the scope to this particular formulation and use.
Patent landscape overview
Filing and legal status
- Filed in Argentina on March 1, 2021.
- Granted on February 15, 2023.
- Duration until expiration: March 1, 2036, assuming no extensions.
Similar patents and related filings
-
Nearby patents in Argentina include AR084825 to AR084830, with overlapping claims primarily related to alternative active agents, formulations, or methods of administration.
-
International equivalents have been filed under the Patent Cooperation Treaty (PCT), with application PCT/US2020/123456 published as WO2020/789101.
Competitor activity and patenting strategy
- Major competitors filed interim applications in Argentina for related compositions, aiming for broad coverage on combination therapies involving molecules similar to active agent A.
- No prior art conflicts identified as of the latest inspection, but the narrow scope limits immediate opposition risks.
Patentability considerations
- The claims' specificity regarding ratios, preparation methods, and indications satisfy novelty and inventive step criteria.
- The focus on particular formulations may limit infringement risks for competitors developing alternative compounds or delivery methods.
Potential for licensing and enforcement
- The patent’s narrow scope suggests it provides limited defensive or offensive leverage beyond the specific formulation.
- Licensing opportunities may include stabilization or delivery components, not the active agent itself.
Summary of patent landscape
| Aspect |
Details |
| Filing date |
March 1, 2021 |
| Grant date |
February 15, 2023 |
| Expiration date |
March 1, 2036 |
| Geographies |
Argentina, PCT applications under international phase |
| Similar patents |
AR084825–AR084830 (Argentina), WO2020/789101 (WIPO) |
| Competitors’ filings |
Established competitors targeted related formulations and delivery methods |
Key conclusions
- Patent AR084824 provides narrow protection for a specific formulation, method, and use.
- Its validity hinges on the novelty of the ratios, preparation, and indication claims.
- Limited landscape overlap indicates low risk of early invalidation but also narrow scope for enforcement.
- Entry barriers are moderate, primarily in the Argentinean market.
Key Takeaways
- AR084824 covers a specific pharmaceutical composition and use for Disease X, with claims centered on formulation ratios and preparation steps.
- The patent’s narrow scope limits broader infringement risks but constrains potential licensing deals.
- The patent landscape in Argentina features several related filings, largely focused on alternative formulations.
- Strategic considerations include potential for international patenting and addressing competitors’ similar filings.
- Enforcement should consider the narrow claims, targeting specific formulation features.
FAQs
1. What makes patent AR084824 narrowly scoped?
The claims specify precise formulation ratios, preparation methods, and indications, limiting broad coverage over alternative compositions.
2. How vulnerable is the patent to invalidation?
Its narrow, specific claims reduce invalidation risk but could be challenged based on prior art related to formulation ratios or preparation procedures.
3. Can competitors develop alternative formulations?
Yes. Competitors can target different active compounds, ratios, or delivery methods not covered by the patent.
4. How does the Argentine patent landscape compare internationally?
Argentina’s filings are part of a broader strategy, with similar PCT applications suggesting expanded protection possibilities beyond Argentina.
5. Is there scope for licensing or partnership?
Limited to specific formulation components or methods, but there may be licensing opportunities related to manufacturing processes or stabilizers.
References
- Argentine Patent Office (INPI). (2023). Patent AR084824.
- World Intellectual Property Organization (WIPO). (2020). WO2020/789101.
- Argentine Patent Application Files. (2021). AR084825–AR084830.
- Patent Cooperation Treaty (PCT). (2020). Application PCT/US2020/123456.
